- Home
- CIFR vs MYGN Comparison
CIFR vs MYGN Comparison
Compare CIFR & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIFR
- MYGN
- Stock Information
- Founded
- CIFR 2021
- MYGN 1991
- Country
- CIFR United States
- MYGN United States
- Employees
- CIFR N/A
- MYGN N/A
- Industry
- CIFR Investment Bankers/Brokers/Service
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CIFR Finance
- MYGN Health Care
- Exchange
- CIFR Nasdaq
- MYGN Nasdaq
- Market Cap
- CIFR 2.4B
- MYGN 2.0B
- IPO Year
- CIFR N/A
- MYGN 1995
- Fundamental
- Price
- CIFR $6.19
- MYGN $16.23
- Analyst Decision
- CIFR Strong Buy
- MYGN Buy
- Analyst Count
- CIFR 9
- MYGN 12
- Target Price
- CIFR $7.42
- MYGN $26.64
- AVG Volume (30 Days)
- CIFR 11.2M
- MYGN 1.0M
- Earning Date
- CIFR 10-31-2024
- MYGN 11-07-2024
- Dividend Yield
- CIFR N/A
- MYGN N/A
- EPS Growth
- CIFR N/A
- MYGN N/A
- EPS
- CIFR N/A
- MYGN N/A
- Revenue
- CIFR $152,466,000.00
- MYGN $823,600,000.00
- Revenue This Year
- CIFR $19.64
- MYGN $13.86
- Revenue Next Year
- CIFR $114.71
- MYGN $5.60
- P/E Ratio
- CIFR N/A
- MYGN N/A
- Revenue Growth
- CIFR 76.34
- MYGN 12.15
- 52 Week Low
- CIFR $2.16
- MYGN $14.72
- 52 Week High
- CIFR $7.99
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- CIFR 51.08
- MYGN 35.57
- Support Level
- CIFR $5.61
- MYGN $15.56
- Resistance Level
- CIFR $7.29
- MYGN $16.73
- Average True Range (ATR)
- CIFR 0.71
- MYGN 0.63
- MACD
- CIFR -0.12
- MYGN 0.41
- Stochastic Oscillator
- CIFR 27.14
- MYGN 75.12
About CIFR Cipher Mining Inc.
Cipher Mining Inc ia an emerging technology company that operates in the Bitcoin mining ecosystem in the United States. The company is developing a cryptocurrency mining business, specializing in Bitcoin. The company is expanding and strengthening the Bitcoin network's critical infrastructure in the United States.
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.